Zobrazeno 1 - 10 of 146 pro vyhledávání: '"Loretta, Gammaitoni"'
1
Akademický článek
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
Autor: Lidia Giraudo, Giulia Cattaneo, Loretta Gammaitoni, Ilenia Iaia, Chiara Donini, Annamaria Massa, Maria Laura Centomo, Marco Basiricò, Elisa Vigna, Alberto Pisacane, Franco Picciotto, Enrico Berrino, Caterina Marchiò, Alessandra Merlini, Luca Paruzzo, Stefano Poletto, Daniela Caravelli, Andrea Michela Biolato, Valentina Bortolot, Elisa Landoni, Marco Ventin, Cristina R. Ferrone, Massimo Aglietta, Gianpietro Dotti, Valeria Leuci, Fabrizio Carnevale-Schianca, Dario Sangiolo
Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-13 (2023)
Abstract Background Even acknowledging the game-changing results achieved in the treatment of metastatic melanoma with the use of immune checkpoint inhibitors (ICI), a large proportion of patients (40–60%) still fail to respond or relapse due to th
Externí odkaz: https://doaj.org/article/3eb42d63a9594f5d95b1ee9f44199df2
Zobrazit plný text záznamu
2
Akademický článek
Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient
Autor: Erica Torchiaro, Consalvo Petti, Sabrina Arena, Francesco Sassi, Giorgia Migliardi, Alfredo Mellano, Roberta Porporato, Marco Basiricò, Loretta Gammaitoni, Enrico Berrino, Monica Montone, Giorgio Corti, Giovanni Crisafulli, Caterina Marchiò, Alberto Bardelli, Enzo Medico
Publikováno v: Frontiers in Oncology, Vol 13 (2023)
High-grade mucinous colorectal cancer (HGM CRC) is particularly aggressive, prone to metastasis and treatment resistance, frequently accompanied by “signet ring” cancer cells. A sizeable fraction of HGM CRCs (20-40%) arises in the context of the
Externí odkaz: https://doaj.org/article/a4d991eacaeb4b91b2c17db7c0dd2e37
Zobrazit plný text záznamu
3
Akademický článek
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
Autor: Ymera Pignochino, Federica Capozzi, Lorenzo D’Ambrosio, Carmine Dell’Aglio, Marco Basiricò, Marta Canta, Annalisa Lorenzato, Francesca Vignolo Lutati, Sandra Aliberti, Erica Palesandro, Paola Boccone, Danilo Galizia, Sara Miano, Giulia Chiabotto, Lucia Napione, Loretta Gammaitoni, Dario Sangiolo, Maria Serena Benassi, Barbara Pasini, Giovanna Chiorino, Massimo Aglietta, Giovanni Grignani
Publikováno v: Molecular Cancer, Vol 16, Iss 1, Pp 1-15 (2017)
Abstract Background Enhancing the antitumor activity of the DNA-damaging drugs is an attractive strategy to improve current treatment options. Trabectedin is an isoquinoline alkylating agent with a peculiar mechanism of action. It binds to minor groo
Externí odkaz: https://doaj.org/article/e058c6685da841f684afb510424d766a
Zobrazit plný text záznamu
8
Supplementary Figure 5 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
Autor: Francesco Leone, Massimo Aglietta, Serena Marchiò, Marco Soster, Giorgia Migliardi, Loretta Gammaitoni, Ivana Sarotto, Caterina Peraldo-Neia, Giuliana Cavalloni
PDF file, 19KB, TUNEL staining of BTC cell lines untreated (NT) and treated (SAR) with Saracatinib at the concentration of 5 �M for 24 hours. A statistical significant increase of apoptosis was seen in all the cell lines ( p-value < 0.05) except in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc95c9f158d0278ddcd99e504851e4f0
https://doi.org/10.1158/1535-7163.22497591
Zobrazit plný text záznamu
9
Supplementary Figure 6 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
Autor: Francesco Leone, Massimo Aglietta, Serena Marchiò, Marco Soster, Giorgia Migliardi, Loretta Gammaitoni, Ivana Sarotto, Caterina Peraldo-Neia, Giuliana Cavalloni
PDF file, 21KB, Ki-67 staining of tumor tissue sections derived from vehicle (A) and Saracatinib treated group (B). A statistical significant decrease of proliferation was seen in treated mice (C) (p-value = 0.0003). NT: vehicle-treated mice.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::546f2204ce5b60a19b54c674bdb8b027
https://doi.org/10.1158/1535-7163.22497588.v1
Zobrazit plný text záznamu
10
Supplementary Figure 3 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
Autor: Francesco Leone, Massimo Aglietta, Serena Marchiò, Marco Soster, Giorgia Migliardi, Loretta Gammaitoni, Ivana Sarotto, Caterina Peraldo-Neia, Giuliana Cavalloni
PDF file, 28KB, Statistical analysis of reduction of cell proliferation by saracatinib in BTC cell lines. A statistical significant inhibition was revealed up to 1.25 �M in all the cell lines, except for TGBC1, in which no significance was found. I
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ddbee52f528d556a8f48c7b814a0b5b
https://doi.org/10.1158/1535-7163.22497597.v1
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje